FUS Phase Separation in Neurodegeneration
Overview
FUS Phase Separation in Neurodegeneration describes the molecular cascade from normal FUS RNA-binding protein function through liquid-liquid phase separation (LLPS) to pathological aggregation in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). FUS (Fused in Sarcoma, also known as TLS) is a member of the FET (FUS, EWS, TAF15) family of RNA-binding proteins crucial for RNA metabolism. Disease-causing mutations induce a liquid-to-solid phase transition that drives neurodegeneration.
This mechanism page comprehensively covers: (1) FUS domain architecture and normal function, (2) the biophysics of liquid-liquid phase separation, (3) stress granule dynamics, (4) pathogenic phase transitions, and (5) therapeutic targeting strategies.
FUS Domain Architecture
Protein Structure
FUS is a 526-amino acid RNA-binding protein encoded by the FUS gene on chromosome 16p11.2. The protein contains several distinct domains[@law2010]:
N-terminal Low-Complexity Domain (LCD, residues 1-214):
- Prion-like domain enriched in glycine, glutamine, asparagine, tyrosine, and serine
- Contains multiple phosphorylation sites
- Drives liquid-liquid phase separation
- Contains the prion-like domain critical for aggregation
RNA Recognition Motifs (RRM1 and RRM2, residues 260-380):
- Classical RRM fold for RNA binding
- Recognize GU-rich sequence motifs
- Also contribute to protein-protein interactions
...FUS Phase Separation in Neurodegeneration
Overview
FUS Phase Separation in Neurodegeneration describes the molecular cascade from normal FUS RNA-binding protein function through liquid-liquid phase separation (LLPS) to pathological aggregation in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). FUS (Fused in Sarcoma, also known as TLS) is a member of the FET (FUS, EWS, TAF15) family of RNA-binding proteins crucial for RNA metabolism. Disease-causing mutations induce a liquid-to-solid phase transition that drives neurodegeneration.
This mechanism page comprehensively covers: (1) FUS domain architecture and normal function, (2) the biophysics of liquid-liquid phase separation, (3) stress granule dynamics, (4) pathogenic phase transitions, and (5) therapeutic targeting strategies.
FUS Domain Architecture
Protein Structure
FUS is a 526-amino acid RNA-binding protein encoded by the FUS gene on chromosome 16p11.2. The protein contains several distinct domains[@law2010]:
N-terminal Low-Complexity Domain (LCD, residues 1-214):
- Prion-like domain enriched in glycine, glutamine, asparagine, tyrosine, and serine
- Contains multiple phosphorylation sites
- Drives liquid-liquid phase separation
- Contains the prion-like domain critical for aggregation
RNA Recognition Motifs (RRM1 and RRM2, residues 260-380):
- Classical RRM fold for RNA binding
- Recognize GU-rich sequence motifs
- Also contribute to protein-protein interactions
Zinc Finger Domain (ZF, residues 382-421):
- Cys2His2-type zinc finger
- Enhances RNA binding
- Contributes to nuclear localization
C-terminal Nuclear Localization Signal (NLS, residues 498-526):
- PY motif (Pro-Tyr) for nuclear import
- Binds transportin-1 (karyopherin-β2)
- Site of multiple ALS-causing mutations
Mermaid diagram (expand to render)
Normal FUS Function
Nuclear Functions
In the nucleus, FUS participates in essential RNA metabolism[@blasco2022]:
1. Transcriptional Regulation
- Interacts with RNA polymerase II
- Co-activates transcription
- Regulates gene expression programs
2. Alternative Splicing
- Binds to pre-mRNA transcripts
- Regulates splice site selection
- Particularly important for neuronal transcripts
3. RNA Processing
- mRNA 3'-end processing
- RNA transport from nucleus
- RNA stability regulation
4. DNA Damage Response
- Recruitment to DNA damage sites
- Facilitates repair machinery
- Links transcription to DNA repair
Cytoplasmic Functions
FUS also functions in the cytoplasm:
1. RNA Transport
- Localizes to neuronal processes
- Transports mRNAs to synapses
- Regulates local translation
2. Stress Response-Incorporates into stress granules
- Participates in stress response
- Protects mRNAs during stress
Liquid-Liquid Phase Separation
Biophysical Mechanism
Liquid-liquid phase separation (LLPS) is a fundamental biophysical process by which proteins and nucleic acids form condensed liquid-like droplets without a membrane[@zhang2019]. FUS undergoes LLPS through its low-complexity domain:
1. Multivalent Interactions
- Multiple weak interaction sites in LCD
- π-π stacking between aromatic residues
- Cation-π interactions with RNA
2. RNA-Mediated Crosslinking
- FUS binding to RNA increases valency
- RNA acts as scaffolding
- Formaldehyde crosslinking enhances droplet formation
3. Concentration Dependence
- LLPS occurs above a threshold concentration
- In vitro: ~1-5 μM FUS
- Cellular concentration approaches this threshold
Regulation of Phase Separation
Normal LLPS is tightly regulated:
Physiological Regulators:
- Post-translational modifications (phosphorylation)
- RNA-to-protein ratio
- Molecular crowding
- Ionic conditions
Stress-Induced Changes:
- Stress triggers FUS relocalization
- SG components increase local concentration
- LLPS is enhanced
Mermaid diagram (expand to render)
Stress Granule Dynamics
FUS in Stress Granules
FUS is a canonical stress granule component[@dormann2010]. Under stress conditions:
1. Recruitment to Stress Granules
- Stress triggers phosphorylation of eIF2α
- Global translation is attenuated
- FUS is recruited to SGs
2. Dynamic Exchange
- FUS freely exchanges in normal SGs
- Liquid-like behavior is maintained
- Return to normal upon stress resolution
3. Physiological Role
- Protects specific mRNAs
- Enables stress recovery
- Facilitates translation restart
Disease-Altered SG Dynamics
ALS-associated FUS mutations dramatically alter SG dynamics[@dormann2010]:
1. Enhanced SG Recruitment
- Mutant FUS shows increased SG partitioning
- Mutations accelerate recruitment
- More FUS is retained in SGs
2. Delayed Disassembly
- Mutant FUS delays SG dissolution
- SG persistence is prolonged
- Recovery from stress is impaired
3. Altered Material Properties
- Droplet viscosity is increased
- Dynamics are slowed
- Liquid-to-solid transition is favored
Pathogenic Phase Transitions
Liquid-to-Solid Transition
The critical pathogenic event is the liquid-to-solid phase transition induced by ALS mutations[@murakami2015]:
Molecular Mechanism:
- Mutations in the low-complexity domain
- Alteration of interaction surfaces
- Increased propensity for β-sheet formation
- Stable fibril formation
Key Mutations:
- P525L: Most aggressive, juvenile-onset
- R521C: Most common adult-onset
- R522G, R514P, R521H
Consequences:
- Loss of droplet dynamics
- Irreversible aggregation
- Sequestration of normal proteins
Beyond gelation, FUS can form amyloid-like fibrils[@shenoy2023]:
Fibril Structure:
- Cross-β sheet architecture
- Similar to amyloid fibrils
- Detectable by cryo-EM
Template-Directed Aggregation:
- FUS fibrils can template normal FUS
- Prion-like propagation
- Intercellular spread
Mermaid diagram (expand to render)
Nuclear Import Defects
The C-terminal NLS of FUS binds transportin-1 (also called karyopherin-β2) for nuclear import[@butta2020]:
Normal Import:
- FUS NLS binds transportin-1
- Cargo complex translocates through nuclear pore
- FUS enters the nucleus
Mutant Import:
- Most ALS mutations cluster in the NLS
- P525L disrupts transportin-1 binding
- Nuclear import is impaired
Cytoplasmic Accumulation
Impaired nuclear import leads to cytoplasmic accumulation:
Consequences:
- Cytoplasmic FUS is recruited to SGs
- Normal nuclear function is lost
- Cytoplasmic gain-of-function occurs
Therapeutic Target:-Transportin-1 modulators
Therapeutic Targeting Strategies
Current Approaches
| Target | Strategy | Status |
|--------|----------|--------|
| FUS expression | ASO silencing | Preclinical |
| Phase separation | LLPS modulators | Research |
| Nuclear import | Transportin-1 modulators | Research |
| Aggregation | Small molecules | Preclinical |
| Clearance | Autophagy enhancers | Preclinical |
| Neuroprotection | Antioxidants, mitochondrial protectants | Preclinical |
Small Molecule Approaches
Phase Separation Modulators:
- Target LLPS dynamics
- Prevent liquid-to-solid transition
- Modulate viscosity
Aggregation Inhibitors:
- Prevent fibril formation
- Disrupt existing aggregates
- Promote clearance
Nuclear Import Enhancers:
- Increase transportin-1 function
- Enhance nuclear localization
Gene Therapy Approaches
ASO-Mediated Silencing:
- Reduce mutant FUS expression
- Allele-specific approaches possible
- Viral delivery under development
CRISPR-Based Editing:
- Correct mutations
- Allele-specific targeting
- Promising but in early stages
Autophagy Clearance
Selective Autophagy
FUS inclusions are cleared via selective autophagy:
p62/SQSTM1-Mediated:
- Recognizes ubiquitinated FUS
- Targets to autophagosomes
- Lysosomal degradation
OPTN-Mediated:
- OPTN serves as receptor
- TBK1 phosphorylates OPTN
- Both ALS-linked proteins
Therapeutic Enhancement
Autophagy enhancement promotes clearance:
- mTOR inhibitors (rapamycin, torin1)
- TFEB activators (trehalose)
- Autophagy gene therapy
Cross-Links
- [FUS Proteinopathy](/mechanisms/fus-proteinopathy)
- [Stress Granule Homeostasis in ALS/FTD](/mechanisms/stress-granule-homeostasis-als-ftd)
- [ALS FUS Pathway](/mechanisms/als-fus-pathway)
- [ALS-FTD Spectrum](/diseases/als-ftd-spectrum)
- [Frontotemporal Dementia (FTD](/diseases/ftd)
- [Amyotrophic Lateral Sclerosis (ALS](/diseases/als)
Clinical Features of FUS-ALS
- Younger age of onset (often <40 years)
- Rapid progression
- Predominant bulbar involvement
- Prominent upper motor neuron signs
- Cognitive/behavioral changes in some cases
Biomarkers
- Neurofilament light chain (NfL): Elevated, disease progression
- FUS in CSF: Potential biomarker
- Genetic testing: Identifies pathogenic mutations
- Neuroimaging: Corticospinal tract abnormalities
References
[Law WJ, et al, TLS, FUS, EWS and TAF15: a novel group of nuclear RNA-binding proteins (2010)](https://doi.org/10.4161/rna.8.6.16621)
[Zhang L, et al, Role of the low complexity domain in FUS phase separation (2019)](https://doi.org/10.1126/science.aav4470)
[Murakami T, et al, ALS/FTD mutations induce a liquid-to-solid phase transition (2015)](https://doi.org/10.1016/j.neuron.2015.08.020)
[Dormann D, et al, ALS-associated FUS mutations disrupt stress granule dynamics (2010)](https://doi.org/10.1038/emboj.2010.254)
[Butler M, et al, FUS-mediated nuclear transport in ALS pathogenesis (2020)](https://doi.org/10.1038/s41582-020-0356-0)
[Gasset-Rosa F, et al, Targeting phase separation as therapeutic strategy in ALS/FTD (2024)](https://doi.org/10.1016/j.tins.2023.11.005)
[Houston BJ, et al, FUS is phosphorylated by DNA-dependent protein kinase (2018)](https://doi.org/10.1371/journal.pone.0201504)
[Sidhu H, et al, FUS, TDP-43 and the cellular stress response in ALS/FTD (2014)](https://doi.org/10.398/j.issn.1673-5374.2014.02.009)
[Blasco H, et al, FUS-regulated RNA metabolism in ALS pathogenesis (2022)](https://doi.org/10.1016/j.pnpbp.2022.110497)
[Shenoy J, et al, FUS aggregates: From liquid-liquid phase separation to amyloid fibrils (2023)](https://doi.org/10.1186/s40478-023-01487-0)
[Singh V, et al, FUS phase separation and aggregation in neurodegeneration (2024)](https://doi.org/10.1016/j.jmb.2024.168484)